Biokin’s new cancer drug secures historic approval in China, but Western regulatory hurdles loom
Backed by an $8.4 billion international licensing deal with Bristol Myers Squibb, Biokin’s groundbreaking dual-target therapy…
Latest
- Spacecom raises $1 billion in record funding round to build out satellite constellation
- China’s humanoid robot boom is still a game of money as demand lags
- Didi’s domestic strength masks overseas drag
- Xiaohongshu quietly open-sources AI model as content platforms build their own foundations
- Unitree’s $66 billion IPO frenzy masks three major hurdles ahead
